Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Plerixafor - Sanofi Genzyme

Drug Profile

Plerixafor - Sanofi Genzyme

Alternative Names: AMD 3100; JM 3100; Mozobil; Plerixafor-hydrochloride; SDZ SID 791

Latest Information Update: 11 Apr 2020

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Genzyme Corporation; Rega Institute for Medical Research
  • Developer Dana-Farber Cancer Institute; Memorial Sloan-Kettering Cancer Center; Sanofi; Sanofi Genzyme
  • Class Antineoplastics; Heterocyclic compounds; Polyamines; Small molecules
  • Mechanism of Action CXCR4 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Stem cell mobilisation
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Stem cell mobilisation
  • Phase II Glioma
  • Phase I/II Acute myeloid leukaemia; Multiple myeloma
  • No development reported Chronic lymphocytic leukaemia; Myocardial infarction; Sickle cell anaemia
  • Discontinued HIV infections; Rheumatoid arthritis

Most Recent Events

  • 14 Dec 2018 Sanofi and CCTU- Cancer Theme completes the phase I CAM-PLEX trial for Pancreatic, Ovarian and Colorectal adenocarcinomas in United Kingdom (NCT02179970)
  • 04 Dec 2018 Phase-II clinical trials in Glioma (Combination therapy, Late-stage disease) in USA (IV) (NCT03746080)
  • 24 Jun 2018 Biomarkers information updated
Restricted Access

If your organization has a subscription then there are several options available to help you access AdisInsight while working remotely. Contact us at AsktheExpert.AdisInsight@springer.com to find out more.
Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top